Together, protective Vγ2Vδ2 T effector cells, CD4+ Th1, CD8+ T effectors, and Foxp3+ Treg, along with their production of anti-TB cytokines, may serve as the mechanisms underlying adjunctive ZOL/IL2 therapeutics against MDR-TB. The gene discussed is CD4; the disease is tuberculosis.